23 July 2020  
EMA/381090/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Crysvita 
burosumab 
On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Crysvita. 
The marketing authorisation holder for this medicinal product is Kyowa Kirin Holdings B.V. 
The CHMP adopted a change and an extension to the existing indication as follows:2 
“Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and 
adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. in 
children 1 year of age and older and adolescents with growing skeletons.”. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
 
